CRM vs MSFT: Which Is the Better Buy?

Side-by-side comparison of Salesforce, Inc. and Microsoft Corporation โ€” fair value, conviction, valuation metrics, and QuantHub research signals. Updated 2026-09-22.
Salesforce, Inc. ยท Technology
$236.42
+11.6% upside to fair value
Med Conviction Grade B High Quality
VS
Microsoft Corporation ยท Technology
$497.12
+41.3% upside to fair value
High Conviction Grade A High Quality
QuantHub Verdict
MSFT has more upside to fair value (+41.3%). These are model outputs โ€” not personalized investment advice. See all research โ†’
Valuation & Fundamentals
Metric CRM MSFT
Current Price $236.42 $497.12
Fair Value Estimate $263.88 $702.35
Upside to Fair Value +11.6% +41.3%
Market Cap $193.6B $3,691.4B
Forward P/E โ€” โ€”
EV / EBITDA 14.4x 18.3x
Price / Sales 4.4x 11.1x
Price / FCF 12.8x 55.1x
Revenue Growth YoY +10.8% +17.7%
Gross Margin 77.3% 67.9%
Operating Margin 21.4% 46.8%
Return on Equity 20.2% 33.2%
Dividend Yield 0.73% 0.73%
FCF Yield 7.82% 1.81%
Analyst Consensus Buy Strong Buy
Investment Thesis
CRM โ€” Salesforce, Inc.
Salesforce is the leading enterprise customer relationship management platform, spanning Sales, Service, Platform, Marketing, Commerce, Tableau, MuleSoft, and Slack under the Customer 360 umbrella, with 83,334 employees and a business that converts $53.65 of revenue per share into $18.48 of free cash flow per share. Business quality is high: TTM gross margin of 77.3%, TTM operating margin of 21.4โ€ฆ
MSFT โ€” Microsoft Corporation
Microsoft is a global infrastructure-software platform spanning Azure, Microsoft 365, security, Dynamics, Windows, GitHub and AI copilots, with high business quality supported by enterprise distribution, explicitly cited switching costs, a $678 billion commercial RPO balance, 67.9% TTM gross margin, 46.8% TTM operating margin, 40.3% TTM net margin and 33.2% ROE. Revenue grew 17.7% and earnings grโ€ฆ
Accumulation Zones
Metric CRM MSFT
Zone Low $197.91 $526.76
Zone High $224.30 $597.00
In Buy Zone? No Yes
โ† CRM Research    MSFT Research โ†’    All Research